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6-month group. Overall, fatal and nonfatal VTE during and after treatment
occurred in 8% of those receiving 3 months of anticoagulation (n 31) and
in 8% of those receiving 6 months anticoagulation (n  29; P  .80; 95%
confidence interval [CI] difference, –3.1% to 4.7%). No patients in either
group had a fatal hemorrhage during treatment, but there were eight major
hemorrhages in those treated for 6 months and none in those treated for 3
months (P .008; 95% CI, –3.5% to –0.7%). Adverse events occurred in 8%
of the patients receiving 3 months of anticoagulation (n 31) and in 9% of
the patients receiving 6 months of anticoagulation (n 35; P .79, 95% CI
–4.9% to 3.2%).
Comment: The data with regard to the hard end points in this
study—death from VTE or major hemorrhage—are likely reliable. The data
with respect to recurrence, extension, or failure to resolve VTE are likely
highly unreliable because they were derived from review forms completed by
clinicians at each individual site, without specific requirements for imaging
during follow-up. Indeed, the idea that the DVT resolved in 95% of the
patients treated with oral anticoagulation is completely disparate with regard
to the findings of serial imaging studies in patients with DVT. The authors
also provide no information about possible postphlebitic syndrome in their
patients. Follow-up is too short for such an analysis. Overall, the study
indicates no difference in death from VTE with 3 or 6 months of anticoag-
ulation in a patient with VTE and unidentified risk factors. The data are not
sufficient to conclude that there is no difference in recurrence of VTE with
the two treatment paradigms.
Heritability of Platelet Responsiveness to Aspirin in Activation Path-
ways Directly and Indirectly Related to Cyclooxygenase-1
Faraday N, Yanek LR, Mathias R, et al. Circulation 2007;115:2490-6.
Conclusion: There is a genetic basis to variability in residual platelet
function after aspirin exposure.
Summary: It is known that the inability of aspirin to suppress platelet
function can be associated with future risk of myocardial infarction, stroke,
and cardiovascular death. The authors sought to determine if there was
genetic variation that could be linked to insufficient aspirin responsiveness.
Aspirin responsiveness was assessed in 1880 asymptomatic patients.
The mean age was 44  13 years, and 58% were women. Patients were
recruited from 309 white and 208 black families with premature coronary
heart disease. Platelet function was determined ex vivo before and after
ingestion of aspirin (81mg/d for 2 weeks). Platelet function was determined
with a panel of tests assessing platelet activation in pathways indirectly and
directly related to cyclooxygenase-1 (COX-1). Multivariable regression
analysis was also used to determine the proportion of phenotypic variance
related to coronary heart disease risk factor covariates.
Arachidonic acid–induced thromboxane B2 production was inhibited
by99% with aspirin (P .0001). Platelet activation by pathways indirectly
related to COX-1 and inhibition of urinary thromboxane excretion was
more variable, with inhibition rates varying from 0% to 100%. Covariates
contributed somewhat to variability in aspirin responsiveness (r2  0.001-
0.133). Direct COX-1 phenotypes were not heritable across races. Pheno-
types indirectly related to COX-1 were consistently and strongly heritable
across races (r2  0.266-0.762; P  .01).
Comment: This is the first study to demonstrate that responsiveness to
aspirin is highly heritable. This applies particularly to phenotypic responses
in activation pathways that are indirectly related to COX-1. The study is also
the first to demonstrate that heritable factors contribute more strongly than
traditional cardiac risk factors to individual variability in residual platelet
function after aspirin exposure. It may be that inadequate response to aspirin
therapy runs in families.
Mid-term Survival After Abdominal Aortic Aneurysm Surgery Pre-
dicted by Cardiopulmonary Exercise Testing
Carlisle J, Swart M. Br J Surg 2007;94:966-9.
Conclusion:Cardiopulmonary exercise (CPX) testing, in combination
with comorbidity scoring, identifies patients unlikely to survive in the
mid-term after successful abdominal aortic aneurysm (AAA) repair.
Summary: The purpose of AAA repair is to prevent aneurysm-related
death. Patients at high risk of death from other causes are unlikely to benefit
overall from AAA repair. A number of risk factors found on history and
physical examinations correlate with survival after surgery. CPX testing
identifies patients at increase risk of dying after surgery (Chest 1999;116:
355-62). In this study the authors sought to determine whether preopera-
tive CPX testing could predict survival after elective open AAA repair.
Patients were also assessed with the Simplified Acute Physiology Score
(SAPS) II, the Acute Physiology and Chronic Health Evaluation
(APACHE) II score, and the Physiological and Operative Severity Score for
the enUmeration of Mortality and morbidity (POSSUM). CPX fitness was
determined with equipment measuring ventilatory minute volume, oxygen
consumption, and carbon dioxide while subjects pedaled an exercise bicycle.
Four variables were derived from CPX exercise measurements: anaerobic
threshold, peak oxygen consumption (V˙O2 peak), and ventilatory equiva-
lents for oxygen (V˙E/O2) and carbon dioxide (V˙E/V˙CO2). The Revised
Cardiac Risk Index (RCRI) was also determined for each patient, with one
point assigned for AAA repair, history of ischemic heart disease, history of
heart failure, cerebrovascular disease, insulin-dependent diabetes, and a
preoperative serum creatinine concentration of about 177 mol/L.
Multivariable analysis indicated that survival to 30 days and for the total
observation period correlated best with V˙E/V˙CO2. An increase in V˙E/
V˙CO2 by one unit increased the hazard ratio for death over the total
observation period by 1.13 for each unit increase. RCRI was also associated
with mid-term survival, as was anaerobic threshold.
Unfit patients were then defined as those with an RCRI 1 and a
V˙E/V˙CO2 of42, and fit patients were then defined as those with an RCRI
of 1 (and any V˙E/V˙CO2), or an RCRI 1 but V˙E/V˙CO2 43. This
definition provided 30 unfit patients and 100 fit patients for analysis. The 30
unfit patients were followed up for a total of 58 patient-years, and the 100 fit
patients for a total of 278 patient-years. Two-year survival for the fit patients
was 97%. Two-year survival for the unfit patients was 55% (95% confidence
interval, 18%-65%; P 178 .001).
Comment: A significant problem with this study is that the distinction
between fit and unfit patients was determined by observed mortality. Addi-
tional data based on prospective classification of patients undergoing open
AAA repair is required to assess whether the retrospective analysis used to
determine fit vs unfit potentially overestimated differences between groups.
Nevertheless, it is unlikely that even patients with relatively large AAAs
would experience a 55% rupture rate 2 years. The data suggest, as previ-
ously suggested by the Endovascular Aneurysm Repair II Trial (Lancet
2005;365:2187-92), that repair of AAAs in the marginally fit or unfit patient
may be more about surgical technical skill than overall patient benefit.
Impact of Endoluminal Treatment on Small Abdominal Aortic Aneu-
rysm: Aneurysm Sac Regression and Secondary Interventions With 5
Years of Follow-up
Hao Bui, Lujan R, Nguyen A, et al. Vasc Endovasc Surg 2007;41:294-300.
Conclusion: Endovascular intervention for small abdominal aortic
aneurysms (AAAs) does not result in faster aneurysm sac regression or lower
rates of secondary intervention.
Summary: It has been suggested endovascular repair be applied to
small AAAs in an attempt to reduce secondary intervention rates associated
with endovascular repair of larger AAAs. The authors reviewed 374 patients
who underwent endovascular AAA repair between 1996 and 2006. Of these
patients, 75 (20%) had a small AAA defined by an aneurysm sac diameter to
aortic diameter ratio of2 at the level of the renal arteries, and 299 patients
had larger AAAs.
There were no significant differences in operative times or operative
blood loss in patients undergoing endovascular repair for small AAAs vs
those undergoing repair of larger AAAs. In the patients treated for small
AAAs, 25.3% developed endoleaks compared with 36.1% of patients treated
for larger AAAs (P  .1). Over a mean follow-up of 42 months (range,
1-109 months), 11 patients (14.7%) with small AAAs had secondary inter-
ventions. Of the patients with larger AAAs, 58 (19.4%) had secondary
interventions (P .41). At 5 years, small AAAs had a 2.5% regression in the
aneurysm sac volume but a 3.0% increase in aneurysm diameter. Patients
with large AAAs had slight increases in sac diameter (3.3%) at 1 month but
steady decreases in sac volume (–13.4%) and aneurysm diameter (–8.8%)
over 5 years.
Comment: The data argue against early intervention with endovascu-
lar techniques for small AAAs. Previous data from the University of Texas
Southwestern Medical Center suggests waiting for small AAAs to enlarge to
5 to 5.5 cm does not reduce the applicability of endovascular techniques for
their repair. Given those data, the relatively benign natural history of small
AAAs, and the data presented here, it seems difficult to justify repair of small
AAAs with endovascular techniques outside the context of a clinical trial.
Renal Insufficiency Following Contrast Media Administration Trial
(REMEDIAL): A Randomized Comparison of 3 Preventive Strategies
Briguori C, Airoldi F, D’Andrea D, et al. Circulation 2007;115:1211-7.
Conclusion: A combination of volume supplementation by sodium
bicarbonate plus N-acetylcysteine (NAC) provides better renal protection
after contrast administration in patients with chronic kidney disease (CKD)
than strategies of hydration with a combination of normal saline andNAC or
the addition of ascorbic acid.
Summary:The optimal strategy for preventing contrast agent–induced
nephrotoxicity (CIN) in patients with CKD is uncertain. Guidelines suggest
volume expansion with saline, along with use of low or iso-osmolar contrast
agents and limits on the volume of contrast agent (Kidney Int 2006;69:S51-
3). Additional strategies focus on the use of antioxidants because reactive
oxygen species are considered an important pathophysiologic cause of CIN
(Kidney Int 2005;68:14-22). Both NAC and ascorbic acid have antioxidant
properties.
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 6 Abstracts 1307
The authors sought to determine efficiency in preventing CIN in patients
with CKD after administration of contrast agents. Of 326 consecutive patients
with CKD undergoing coronary or peripheral procedures, or both, 111 were
assigned randomly to prophylactic administration of 0.9% saline infusion plus
NAC, 107 to 0.9% saline plus ascorbic acid plus NAC, and 108 to sodium
bicarbonate infusion plus NAC. All patients had an estimated glomerular
filtration rate of 40 mL/min and a serum creatinine level 2 mg/dL. A
contrast nephropathy risk score was calculated for each patient. An iso-osmolar,
nonionic contrast agent (iodixanol) was used. A 25% increase in creatinine
level 48 hours after the procedure was considered the primary end point of the
study. Similar amounts of contrastmedia were administered to each group (P
.69), and contrast nephropathy risk scores were also similar (P  .21). In the
saline plus NAC group, CIN occurred in 11 of 111 (9.9%). In the bicarbonate
plus NAC group, CIN occurred in 2 of 108 (1.9%; P .019). CIN occurred in
11 of 107 patients (10.3%) in the saline plus ascorbic acid plusNACgroup (P
1.00 vs saline plus NAC group).
Comment: The study calls into question the concept of reactive
oxygen species as an important pathophysiologic cause of CIN and suggests
a different protective mechanism of action for bicarbonate. Additional
studies will need to be performed to determine whether a combination of
antioxidant therapy plus bicarbonate is even more efficacious than bicarbon-
ate therapy alone.
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